Loading companies…
Loading companies…
France · Biotech · Healthtech · Enterprise software
Developing next-generation biologics for severe immunological and inflammatory diseases
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | $165M | Apollo Health Ventures — Role not disclosedArkin Bio Capital — Role not disclosedJeito Capital — Role not disclosedSanofi Ventures — Role not disclosedSixty Degree Capital — Role not disclosedSofinnova Partners — Role not disclosedVives Partners — Role not disclosed |